ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group


Please enter your username and password.




ANZMTG 01.15 CHARLI Trial - An open-labelled, non-comparative, multisite, two arm Phase Ib/II study investigating checkpoint and RANK-Ligand inhibition

This research project is testing the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma. A human monoclonal antibody targeting RANK-L, denosumab has been used for many years to help treat cancers such as prostate and breast cancers, but it is not currently used in melanoma. We hope the addition of denosumab to current melanoma therapies will make these treatments work better without adding to the side effects.
Study Status: Open to Recruitment Identifier: NCT03161756
ANZCTR Identifier: ACTRN1261700077347 

Study Co-Chair's Details: 
Dr Shahneen Sandhu and Prof Grant McArthur
Peter MacCallum Cancer Centre

ANZMTG Details: 
Phone: +61 2 9911 7386 

Documents (PDF downloads):

Return to Previous Page